Sentence examples for formulations comprised of from inspiring English sources

A set of user defined design constraints produces a subset of different optimization formulations comprised of different polymer blends, molecular weights, hydrolyzation extents, solvents, and additives.

Biosolids derived organo-mineral fertilisers (OMF) are designed to reduce fertiliser inputs, but may lead to excessive accumulation of soil P. Two OMF formulations comprised of biosolids (BS), urea and potassium at NPK ratios of 10 4 4 (OMF10) and 15:4:4 (OMF15) were investigated.

Antiangiogenic cancer vaccines capable of inducing this kind of damage include formulations comprised of endothelial cell-specific antigens.

Tumor vaccine formulations comprised of tumor antigens seem to be a promising cancer preventive approach, however, targeting tumor endothelium with antiangiogenic vaccines has advantages over targeting tumor cells.

These include formulations comprised of solely the TNF homology domain, of the TNF homology domain with the 75 amino acid stalk that joins the TNF domain to the membrane, and of each of the above joined to an isoleucine zipper trimerization motif [ 9, 10].

The vaccine formulation comprised of PES and the antigen KLH conjugated 80 kDa HSA peptide-1 dissolved in N-methyl-2-pyrrolidone (NMP /NMP-water as solveNMP /NMP-water

The optimized formulation comprised of 2% (w/v) HPC and 1% (w/v) EC, exhibited satisfactory mucodhesive strength, swelling and optimum drug release upto 8 h.

One of the oil formulations used a multifunctional DVII (Dispersant Viscosity Index Improver) component with enhanced antiwear characteristics to improve durability of engine components while the other formulation comprised of a conventional additive package.

In light of these considerations, the aim of the present study was to reverse 5-FU resistance in vitro and in vivo through a two-pronged strategy: combining 5-FU with the d-Ino modulator, and treating tumour cells with our new, stealth liposomal formulation comprised of the aforementioned combination.

XARTEMIS™ XR (previously known as MNK-795, Mallinckrodt Brand Pharmaceuticals, Dublin, Ireland), is the first immediate-release (IR)/extended-release (ER) abuse-deterrent formulation comprised of a fixed-dose combination of oxycodone (7.5 mg) plus acetaminophen (325 mg) that is available on the market.

The formulation comprises of important constraint that the UE be allotted a number of RBs from its acquired demand as in (4).